Full Press Release Details
Inspira Technologies Releases CEO Update: Major
Milestones Signal Next-Level Respiratory Care
Letter from the CEO / March 14, 2025
Ra'anana, Israel - March 14, 2025
- Inspira Technologies OXY B.H.N. Ltd. ("Inspira," "Inspira Technologies" or the "Company")
(Nasdaq: IINN), a pioneering force in the evolution of respiratory support and real-time blood-monitoring technologies, is pleased to
share this update to shareholders from its Chief Executive Officer, Director, and Co-founder, Mr. Dagi Ben Noon.
Dear Valued Shareholders,
We founded Inspira Technologies with a bold vision:
to radically transform life-support for the millions of patients who each year face the harsh realities of mechanical ventilation. Today,
I believe that the INSPIRA ART system we are developing stands poised to become the breakthrough solution that could profoundly reshape
In this letter, I want to provide my perspective
on some of our recent achievements, how they connect to our strategic direction and long term vision, and some details on our upcoming
1. INSPIRA ART500: A Transformational Leap in
At the heart of our mission lies the INSPIRA ART500,
a next-generation device designed to elevate oxygen levels for patients suffering from Acute Respiratory Failure - without resorting to
invasive mechanical ventilation. Our aspiration is straightforward yet revolutionary: replace a significant portion of the estimated 100,000
ventilators in the U.S. with a safer, more human-centered alternative. Each INSPIRA ART500 device is expected to treat dozens of patients
Over the past year, we've observed how similarly
disruptive med-tech companies have generated remarkable investor enthusiasm, often driven by a confluence of regulatory achievements,
compelling market demand, and strategic milestones. We believe the INSPIRA ART500 embodies that same, if not greater, potential for success.
With cost control in mind, we are focusing most of the Company's financial resources on the acceleration of the disruptive INSPIRA
ART500, in light of the product's potential superiority in the competitive landscape and value creation for the Company and its
2. Multi-Pronged Technological Momentum &
Accelerated Path to Market
INSPIRA ART500 is being designed to integrate
multiple cutting-edge core technologies in the Company pipeline - all converging to redefine what's possible in critical care.
Taken together, these innovations are on track for
pivotal studies shortly after the planned INSPIRA ART500 FDA submission - projected within the next 18 months. We believe the synergy
among these technologies could ignite a wave of adoption in intensive care units across the globe.
3. Sizable Market Opportunity & Upcoming 18-Month
The global mechanical ventilation market is estimated
at $19 billion annually. In the United States alone, tens of thousands of ventilators remain the backbone of critical care for severe
respiratory conditions. INSPIRA ART500 aims to become the disruptive force that addresses this massive need with a safe, patient-friendly
and less invasive approach.
In the coming weeks, the Company expects to receive
a prepayment from its U.S. distributor for INSPIRA ART100 systems for planned deployment in select hospitals, a milestone that management
believes underscores near-term revenue potential.
4. Roadmap of Strategic Milestones
To build on this transformative momentum, we are
aligning a series of key milestones to support sustained growth:
5. Envisioning the Future of Critical Care
Once fully integrated, our INSPIRA ART500 is intended
to be equipped with the HYLA blood sensor. The single use patient kit aims to create a new and superior standard of patient-focused care.
By allowing patients to stay awake and actively involved in their own recovery, we're not merely refining mechanical ventilation
- we're redefining it.
6. A Personal Invitation to Our Investors
On behalf of the entire Inspira Technologies team,
I want to thank you for your unwavering support and confidence in our vision. We're determined to lead a global shift in respiratory
care - one that prioritizes patient dignity and significantly reduces the complications linked to conventional ventilation.
We invite you to stand with us as we reshape the
landscape of acute respiratory care for millions of patients worldwide. Together, we have the opportunity to drive a wave of positive
change in an industry that's ripe for disruption.
CEO, Director, and Co-founder
Inspira Technologies
About Inspira Technologies
Inspira Technologies is developing innovative respiratory
support and diagnostics technologies. The Company's flagship INSPIRA ART500 system also known as the INSPIRA ART aims to revolutionize
critical care by enabling patients to remain awake during treatment while stabilizing oxygen levels without mechanical ventilation. The
FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in both the U.S. and for Cardiopulmonary
Bypass procedures and Extra Corporeal Membrane Oxygenation in Israel. The Company's HYLA blood sensor technology is designed to
provide continuous, real-time blood monitoring without the need for blood draws. The Company's pipeline products, including the INSPIRA
ART500, INSPIRA Cardi-ART, and HYLA blood sensor, are currently in development and have not yet received regulatory approval.
For more information, visit: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking
statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management
of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from
those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the
potential benefits of the Company's products and impact on repository care and the market, that the INSPIRA ART500 device is expected
to treat dozens of patients annually, its belief that the INSPIRA ART500 embodies the same or greater potential as other med-tech companies,
the belief that the Company's innovations are on track for pivotal studies shortly after the planned INSPIRA ART FDA submission
and that synergy among these technologies could ignite a wave of adoption in intensive care units worldwide, the expected timing of the
FDA submission of the ART500, the HYLA blood sensor and single-use patient kit, the estimated size of the global mechanical ventilation
market, the Company's aim to disrupt the existing approach with its technology, that the Company expects to receive prepayment from
its U.S. distributor for its devices for planned deployment in hospitals, the planned integration of the Company's devices, and
the Company's belief that it has the opportunity to disrupt the mechanical ventilation market. These forward-looking statements
and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except
as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements
to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information
about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's
annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"),
which is available on the SEC's website at www.sec.gov.
Technologies - Media Relations
Email: info@inspirao2.com
Phone: +972-9-9664485
Capital Markets & Investor Contact
| Capital Markets Advisors
North American Equities Desk